Ignite Creation Date:
2025-12-24 @ 3:52 PM
Ignite Modification Date:
2026-01-01 @ 2:22 PM
Study NCT ID:
NCT04353492
Status:
COMPLETED
Last Update Posted:
2025-11-12
First Post:
2020-04-16
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-07-14
Start Date Type:
ACTUAL
Primary Completion Date:
2024-10-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-03-11
Completion Date Type:
ACTUAL
First Submit Date:
2020-04-16
First Submit QC Date:
None
Study First Post Date:
2020-04-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-10-07
Results First Submit QC Date:
None
Results First Post Date:
2025-11-12
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-27
Last Update Post Date:
2025-11-12
Last Update Post Date Type:
ESTIMATED